Designed Transcription Activator-Like Effector Proteins Efficiently Induced the Expression of Latent HIV-1 in Latently Infected Cells

被引:0
作者
Wang, Xiaohui [1 ]
Wang, Pengfei [1 ]
Fu, Zheng [1 ]
Ji, Haiyan [1 ]
Qu, Xiying [1 ]
Zeng, Hanxian [1 ]
Zhu, Xiaoli [1 ]
Deng, Junxiao [1 ]
Lu, Panpan [1 ]
Zha, Shijun [1 ]
Song, Zhishuo [1 ]
Zhu, Huanzhang [1 ]
机构
[1] Fudan Univ, Inst Genet, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China
基金
中国国家自然科学基金;
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; DNA-BINDING SPECIFICITY; PROVIRAL DNA; T-CELLS; ANTIRETROVIRAL THERAPY; GENE-EXPRESSION; TAL EFFECTORS; III EFFECTORS; REPLICATION; RESERVOIRS;
D O I
10.1089/aid.2014.0121
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
HIV latency is the foremost barrier to clearing HIV infection from patients. Reactivation of latent HIV-1 represents a promising strategy to deplete these viral reservoirs. Here, we report a novel approach to reactivate latent HIV-1 provirus using artificially designed transcription activator-like effector (TALE) fusion proteins containing a DNA-binding domain specifically targeting the HIV-1 promoter and the herpes simplex virus-based transcriptional activator VP64 domain. We engineered four TALE genes (TALE1-4) encoding TALE proteins, each specifically targeting different 20-bp DNA sequences within the HIV-1 promoter, and we constructed four TALE-VP64 expression vectors corresponding to TALE1-4. We found that TALE1-VP64 effectively reactivated HIV-1 gene expression in latently infected C11 and A10.6 cells. We further confirmed that TALE1-VP64 reactivated latent HIV-1 via specific binding to the HIV-LTR promoter. Moreover, we also found that TALE1-VP64 did not affect cell proliferation or cell cycle distribution. Taken together, our data demonstrated that TALE1-VP64 can specifically and effectively reactivate latent HIV-1 transcription, suggesting that this strategy may provide a novel approach for anti-HIV-1 latency therapy in the future.
引用
收藏
页码:98 / 106
页数:9
相关论文
共 45 条
  • [1] Prospects for Treatment of Latent HIV
    Barton, K. M.
    Burch, B. D.
    Soriano-Sarabia, N.
    Margolis, D. M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (01) : 46 - 56
  • [2] Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors
    Boch, Jens
    Scholze, Heidi
    Schornack, Sebastian
    Landgraf, Angelika
    Hahn, Simone
    Kay, Sabine
    Lahaye, Thomas
    Nickstadt, Anja
    Bonas, Ulla
    [J]. SCIENCE, 2009, 326 (5959) : 1509 - 1512
  • [3] TAL effectors: finding plant genes for disease and defense
    Bogdanove, Adam J.
    Schornack, Sebastian
    Lahaye, Thomas
    [J]. CURRENT OPINION IN PLANT BIOLOGY, 2010, 13 (04) : 394 - 401
  • [4] Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers
    Bultmann, Sebastian
    Morbitzer, Robert
    Schmidt, Christine S.
    Thanisch, Katharina
    Spada, Fabio
    Elsaesser, Janett
    Lahaye, Thomas
    Leonhardt, Heinrich
    [J]. NUCLEIC ACIDS RESEARCH, 2012, 40 (12) : 5368 - 5377
  • [5] Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting
    Cermak, Tomas
    Doyle, Erin L.
    Christian, Michelle
    Wang, Li
    Zhang, Yong
    Schmidt, Clarice
    Baller, Joshua A.
    Somia, Nikunj V.
    Bogdanove, Adam J.
    Voytas, Daniel F.
    [J]. NUCLEIC ACIDS RESEARCH, 2011, 39 (12) : e82
  • [6] Involvement of histone methyltransferase GLP in HIV-1 latency through catalysis of H3K9 dimethylation
    Ding, Donglin
    Qu, Xiying
    Li, Lin
    Zhou, Xin
    Liu, Sijie
    Lin, Shiguan
    Wang, Pengfei
    Liu, Shaohui
    Kong, Chuijin
    Wang, Xiaohui
    Liu, Lin
    Zhu, Huanzhang
    [J]. VIROLOGY, 2013, 440 (02) : 182 - 189
  • [7] Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site
    Eberhardy, SR
    Goncalves, J
    Coelho, S
    Segal, DJ
    Berkhout, B
    Barbas, CF
    [J]. JOURNAL OF VIROLOGY, 2006, 80 (06) : 2873 - 2883
  • [8] Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
    Ebina, Hirotaka
    Misawa, Naoko
    Kanemura, Yuka
    Koyanagi, Yoshio
    [J]. SCIENTIFIC REPORTS, 2013, 3
  • [9] Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
    Finzi, D
    Hermankova, M
    Pierson, T
    Carruth, LM
    Buck, C
    Chaisson, RE
    Quinn, TC
    Chadwick, K
    Margolick, J
    Brookmeyer, R
    Gallant, J
    Markowitz, M
    Ho, DD
    Richman, DD
    Siliciano, RF
    [J]. SCIENCE, 1997, 278 (5341) : 1295 - 1300
  • [10] GAYNOR RB, 1995, CURR TOP MICROBIOL, V193, P51